Skip to content

Study · Animal study (in vivo) · wistar rat · 2014

6 results

Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats.

Rodriguez Salgueiro S, González Núñez L, García Del Barco Herrera D, Santos Febles E, Maza Ares D, Millares López R, Berlanga Acosta J

Iranian journal of kidney diseases1 Sept 2014Cited by 4 (Europe PMC)

PMID25194405 (opens in a new tab)PepBankPUB-25194405
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given a kanamycin overdose, normal structure of several glomeruli was seen in the GHRP6 group during recovery, but repair was less complete than in the combined group.

    In plain wordsIn rats recovering from kidney injury, GHRP6 was followed by normal structure in some kidney filters, but repair was less complete than with both drugs.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedGlomerular structure in the recovery phase, GHRP6 group
    Study

    Wistar ratn: not reported in source

    Kanamycin overdose kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 20 daysAs given in this study (Wistar rat).

    Source sentences

    Summary
    During the recovery phase, normal structure of several glomeruli and the interstitium was appreciated in the EGF and GHRP6 groups, although tissue repair was not as complete as it in the EGF-GHRP6 group.
    2 context sentences
    Summary · context
    Forty-four male Wistar adults rats were submitted to treatment for 20 days with sodium phosphate saline buffer (control group), kanamycin (kanamycin group), kanamycin and EGF (EGF group), kanamycin and GHRP6 (GHRP6 group), kanamycin, EGF, and GHRP6 (EGF-GHRP6 group).
    Summary · context
    The kidneys were studied both during acute kidney injury (n = 19) and recovery phases (n = 25).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given a kanamycin overdose, normal structure of the interstitium was seen in the GHRP6 group during recovery, but repair was less complete than in the combined group.

    In plain wordsIn rats recovering from kanamycin kidney injury, GHRP6 was followed by normal tissue between kidney tubes, but repair was less complete than with both drugs.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedInterstitial structure in the recovery phase, GHRP6 group
    Study

    Wistar ratn: not reported in source

    Kanamycin overdose kidney injury
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 20 daysAs given in this study (Wistar rat).

    Source sentences

    Summary
    During the recovery phase, normal structure of several glomeruli and the interstitium was appreciated in the EGF and GHRP6 groups, although tissue repair was not as complete as it in the EGF-GHRP6 group.
    2 context sentences
    Summary · context
    Forty-four male Wistar adults rats were submitted to treatment for 20 days with sodium phosphate saline buffer (control group), kanamycin (kanamycin group), kanamycin and EGF (EGF group), kanamycin and GHRP6 (GHRP6 group), kanamycin, EGF, and GHRP6 (EGF-GHRP6 group).
    Summary · context
    The kidneys were studied both during acute kidney injury (n = 19) and recovery phases (n = 25).

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In rats given a kanamycin overdose, cytoprotective treatments (EGF, GHRP6 or both) accelerated recovery of tubular damage, and reversible tubular changes prevailed.

    In plain wordsIn rats recovering from kanamycin kidney injury, EGF, GHRP6 or both sped up recovery of kidney tube damage.

    Peptide
    GHRP-6
    Outcome
    DecreaseRecovery of tubular damage
    Study

    Wistar ratn = 25

    Kanamycin overdose kidney injury
    Comparator
    Kanamycin group
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    In the recovery phase, cytoprotective treatments accelerated the recovery of tubular damage and reversible tubular changes prevailed.
    2 context sentences
    Summary · context
    Forty-four male Wistar adults rats were submitted to treatment for 20 days with sodium phosphate saline buffer (control group), kanamycin (kanamycin group), kanamycin and EGF (EGF group), kanamycin and GHRP6 (GHRP6 group), kanamycin, EGF, and GHRP6 (EGF-GHRP6 group).
    Summary · context
    The kidneys were studied both during acute kidney injury (n = 19) and recovery phases (n = 25).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In rats given a kanamycin overdose, glomerular damage was less in the groups treated with EGF, GHRP6 or both than in the kanamycin group during acute kidney injury.

    In plain wordsIn rats with kanamycin kidney injury, kidney filter damage was smaller in groups treated with EGF, GHRP6 or both than in untreated rats.

    Peptide
    GHRP-6
    Outcome
    DecreaseGlomerular damage during acute kidney injury
    Study

    Wistar ratn = 19

    Kanamycin overdose kidney injury
    Comparator
    Kanamycin group
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    The damage in the glomeruli, proximal tubules, and interstitium was less in the groups treated with the cytoprotective treatments than in kanamycin group during acute kidney injury.
    2 context sentences
    Summary · context
    Forty-four male Wistar adults rats were submitted to treatment for 20 days with sodium phosphate saline buffer (control group), kanamycin (kanamycin group), kanamycin and EGF (EGF group), kanamycin and GHRP6 (GHRP6 group), kanamycin, EGF, and GHRP6 (EGF-GHRP6 group).
    Summary · context
    The kidneys were studied both during acute kidney injury (n = 19) and recovery phases (n = 25).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In rats given a kanamycin overdose, proximal tubular damage was less in the groups treated with EGF, GHRP6 or both than in the kanamycin group during acute kidney injury.

    In plain wordsIn rats with kanamycin kidney injury, kidney tube damage was smaller in groups treated with EGF, GHRP6 or both than in untreated rats.

    Peptide
    GHRP-6
    Outcome
    DecreaseProximal tubule damage during acute kidney injury
    Study

    Wistar ratn = 19

    Kanamycin overdose kidney injury
    Comparator
    Kanamycin group
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    The damage in the glomeruli, proximal tubules, and interstitium was less in the groups treated with the cytoprotective treatments than in kanamycin group during acute kidney injury.
    2 context sentences
    Summary · context
    Forty-four male Wistar adults rats were submitted to treatment for 20 days with sodium phosphate saline buffer (control group), kanamycin (kanamycin group), kanamycin and EGF (EGF group), kanamycin and GHRP6 (GHRP6 group), kanamycin, EGF, and GHRP6 (EGF-GHRP6 group).
    Summary · context
    The kidneys were studied both during acute kidney injury (n = 19) and recovery phases (n = 25).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In rats given a kanamycin overdose, interstitial damage was less in the groups treated with EGF, GHRP6 or both than in the kanamycin group during acute kidney injury.

    In plain wordsIn rats with kanamycin kidney injury, damage between the kidney tubes was smaller in groups treated with EGF, GHRP6 or both than in untreated rats.

    Peptide
    GHRP-6
    Outcome
    DecreaseInterstitial damage during acute kidney injury
    Study

    Wistar ratn = 19

    Kanamycin overdose kidney injury
    Comparator
    Kanamycin group
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    The damage in the glomeruli, proximal tubules, and interstitium was less in the groups treated with the cytoprotective treatments than in kanamycin group during acute kidney injury.
    2 context sentences
    Summary · context
    Forty-four male Wistar adults rats were submitted to treatment for 20 days with sodium phosphate saline buffer (control group), kanamycin (kanamycin group), kanamycin and EGF (EGF group), kanamycin and GHRP6 (GHRP6 group), kanamycin, EGF, and GHRP6 (EGF-GHRP6 group).
    Summary · context
    The kidneys were studied both during acute kidney injury (n = 19) and recovery phases (n = 25).

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.